Cagrilintide – 5mg

Cagrilintide

A study by Larsen et al. (2022) compared cagrilintide to the dual amylin and calcitonin receptor agonist KBP-336 in obese and diabetic rats. The research found that while both agents effectively reduced body weight and improved glycemic control, KBP-336 exhibited superior efficacy, suggesting the importance of receptor activation balance in therapeutic outcomes.

Further exploration into the neural mechanisms of cagrilintide was conducted by a team at the University of Copenhagen (2025). Their cross-species analysis revealed that cagrilintide acts on neurons in the brainstem’s dorsal vagal complex, particularly those expressing calcitonin receptors. In rats, cagrilintide promoted long-term transcriptional changes in these neurons, indicating a sustained impact on appetite regulation and energy balance.

In a clinical context, a phase 2 trial assessed the efficacy of co-administered cagrilintide and semaglutide (CagriSema) in individuals with type 2 diabetes. The combination therapy resulted in greater weight loss and improved glycemic control compared to either agent alone, highlighting the potential benefits of targeting multiple pathways in metabolic disorders (Frias et al., 2023).

Additionally, research by Sun et al. (2024) investigated the combination of cagrilintide with a novel GLP-1 analogue derived from bullfrog. In diet-induced obese mice, this combination led to significant weight reduction and enhanced glucose regulation, surpassing the effects of semaglutide alone.

These findings underscore the therapeutic promise of cagrilintide, both as a monotherapy and in combination with other agents, in managing obesity and related metabolic conditions.

References:

1. Larsen, A. T., Mohamed, K. E., Sonne, N., Bredtoft, E.-M., & Andersen, F. (2022). Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & Pharmacotherapy, 156, 113969. https://pubmed.ncbi.nlm.nih.gov/36242844/
2. University of Copenhagen. (2025). A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mechanisms of Cagrilintide Action. bioRxiv. https://pubmed.ncbi.nlm.nih.gov/39868309/
3. Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., & Lingvay, I. (2023). Efficacy and safety of co-administered once-weekly cagrilintide with once-weekly semaglutide in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 402(10397), 123–134. https://pubmed.ncbi.nlm.nih.gov/37364590/
4. Sun, X., Yang, D., Li, Y., Shi, J., & Zhang, X. (2024). Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy. Peptides, 177, 171203. https://pubmed.ncbi.nlm.nih.gov/38582303/
5. D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2023). Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in Review, 31(1), 45–50. https://pubmed.ncbi.nlm.nih.gov/36883831/